Promoter Hypermethylation of the Eyes Absent 4 Gene Is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients
Autor: | Mohammad Reza Abbaszadegan, Matineh Barati Bagerabad, Mohammad Amin Kerachian, Sahar Tavakolian |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Adult
Male Colorectal cancer Colon Iran Polymerase Chain Reaction 03 medical and health sciences 0302 clinical medicine No Keywords Biomarkers Tumor Medicine Humans 030212 general & internal medicine Epigenetics Stage (cooking) Promoter Regions Genetic Gene Aged DNA Primers Neoplasm Staging Aged 80 and over lcsh:R5-920 EYA4 business.industry Cancer General Medicine Methylation DNA Methylation Middle Aged medicine.disease Gene Expression Regulation Neoplastic Case-Control Studies DNA methylation Cancer research Screening Trans-Activators Biomarker (medicine) Female business Colorectal Neoplasms lcsh:Medicine (General) |
Zdroj: | Acta Medica Iranica, Vol 57, Iss 5 (2019) Acta Medica Iranica, Vol 56, Iss 1 (2018) Scopus-Elsevier |
ISSN: | 1735-9694 0044-6025 |
Popis: | The aim of this study was to investigate whether hypermethylation of Eyes Absent 4 (EYA4) is also implicated in Iranian Colorectal Cancer (CRC) patients or not. From fresh frozen tissues, samples from 38 paired (cancer and normal) CRC tissue specimens were used in this study, the DNA was isolated, sodium bisulfite treated and analyzed by methylation-specific polymerase (MSP) chain reaction using primers specific for unmethylated or methylated promoter sequences of the EYA4 gene. We also analyzed EYA4 mRNA expression using real time RT-PCR. Demographic characteristics of these patients including age, sex, tumor grade, location, stage, and TNM classification were evaluated and the relationship between methylation status of the gene and clinicopathological features was analyzed. Current study indicated that EYA4 promoter hypermethylation has a sensitivity of 81.57% and specificity of 78.94%. Findings showed lower expression of EYA-4 in methylated samples in comparison with its normal adjacent tissue, although it was not significant (P>0.05). No significant associations were observed between EYA4 hypermethylation and the clinicopathological characteristics. Although the clinical patient outcome of our 38 CRC patients was not associated with EYA4 promoter hypermethylation, the high frequency of this methylation and its high sensitivity and specificity to neoplastic cells may qualify EYA4 promoter methylation as a potential candidate screening marker in Iranian population and may help to improve early detection of CRC. |
Databáze: | OpenAIRE |
Externí odkaz: |